Overview

Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B

Status:
Unknown status

Trial end date:
2020-05-31

Target enrollment:

Participant gender:

Summary

This study evaluates the addition of glycyrrhizin to entecavir in the treatment of patients with chronic hepatitis B in China. Half of participants will receive magnesium isoglycyrrhizinate followed by oral diammonium glycyrrhizinate and entecavir in combination, while the other half will receive a placebo and entecavir.

Phase:

Phase 4

Details

Lead Sponsor:

Cttq

Treatments:

Entecavir
Glycyrrhizic Acid